Prognostic value of lncRNA ROR expression in various cancers: a meta-analysis
- PMID: 30076198
- PMCID: PMC6165833
- DOI: 10.1042/BSR20181095
Prognostic value of lncRNA ROR expression in various cancers: a meta-analysis
Abstract
Background: There is a dispute on the prognostic value of long non-coding RNA regulator of reprogramming (lncRNA ROR) in cancers. The purpose of the present study was to evaluate the prognostic significance of lncRNA ROR expression in human cancers. Methods: PubMed, Embase, and Cochrane Library were searched to look for relevant studies. The meta-analyses of prognostic and clinicopathological parameters (CPs) were conducted. Results: A total of ten studies were finally included into the meta-analysis. High lncRNA ROR expression was significantly associated with shorter overall survival (hazard ratio [HR] = 2.88, 95% confidence interval [CI] = 2.16-3.84, P<0.01) and disease-free survival (HR = 3.25, 95% CI = 2.30-4.60, P<0.01) compared with low lncRNA ROR expression. Besides, high lncRNA ROR expression was obviously related to more advanced clinical stage (P<0.01), earlier tumor metastasis (P=0.02), lymph node metastasis (P<0.01), and vascular invasion (P<0.01) compared with low lncRNA ROR expression. However, there was no significant correlation between lncRNA ROR expression and other CPs, including age (P=0.18), gender (P=0.33), tumor size (P=0.25), or tumor differentiation (P=0.13). Conclusion: High lncRNA ROR expression was associated with worse prognosis in cancers. LncRNA ROR expression could serve as an unfavorable prognostic factor in various cancers.
Keywords: cancer; lncRNA ROR; meta-analysis; prognosis.
© 2018 The Author(s).
Conflict of interest statement
The authors declare that there are no competing interests associated with the manuscript.
Figures








References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources